Application of genetic knowledge holds huge potential for the future and some believe that it has potential to become larger than the pharmaceutical market. Here Dr Alward examines what it has offered for the understanding and future treatment of glaucoma. Until recently, breakthroughs in glaucoma genetics emerged from painstaking family research, with the discovery of LOXL1 being the exception.
Study: MERCURY-3 trial results support efficacy of Roclanda
September 13th 2023MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.
2 Clarke Drive
Cranbury, NJ 08512